The plan for the upcoming ROO phase of the award includes finalization of Specific Aim 2 using the clodronated liposomes as an alternate method for mononuclear phagocyte removal {as discussed In """"""""Changes made to alms'), completion of Specific Aim 3 on the effects of GM-CSF on the growth, angiogenesis, and metastases in human breast cancer in immunodeficient mice, and further investigation into monocyte and macrophage subpopulations generated in response to GM-CSF treatment. Thus the Specific Aims will address the following questions: Central Hypothesis (modification from original): GM-CSF treatment induces a phenotype switch In tumor infiltrating mononuclear phagocytes and triggers an anti-angiogenic program.
Specific Aim 2 (from parent grant): To determine the cells responsible for sVEGFR-1 production in response to GM-CSF.
Specific Aim 3 (from parent grant): Does GM-CSF Inhibit tumor growth, angiogenesis, and metastases of human tumors in nude mice? New Aims based on preliminary data generated from the parent grant and/or collaboration:
Specific Aim 4 : To determine if GM-CSF changes mononuclear phagocyte cell phenotypes using gene expression signatures and proteomic evaluation.

Public Health Relevance

Our data suggest that GM-CSF not only inhibits tumor angiogenesis by inducing sVEGFR-1 expression from tumor macrophages, but that it also induces a phenotype switch from M2, tumor helping cells to M1, tumor-fighting cells. Because the presence of infiltrating immune cells like monocytes and macrophages in breast cancer predict a poor outcome, the understanding of the specific phenotypes of these cells and their activity is essential to correlate to which type of cells are responsible for poor prognosis and which subpopulation of macrophages help the patient.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Transition Award (R00)
Project #
5R00CA131552-04
Application #
8131794
Study Section
Special Emphasis Panel (NSS)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2010-09-01
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
4
Fiscal Year
2011
Total Cost
$241,531
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Forget, Mary A; Voorhees, Jeffrey L; Cole, Sara L et al. (2014) Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS One 9:e98623
Chen, Duan; Bobko, Andrey A; Gross, Amy C et al. (2014) Involvement of tumor macrophage HIFs in chemotherapy effectiveness: mathematical modeling of oxygen, pH, and glutathione. PLoS One 9:e107511
Dhimitruka, Ilirian; Bobko, Andrey A; Eubank, Timothy D et al. (2013) Phosphonated trityl probes for concurrent in vivo tissue oxygen and pH monitoring using electron paramagnetic resonance-based techniques. J Am Chem Soc 135:5904-10
Szomolay, Barbara; Eubank, Tim D; Roberts, Ryan D et al. (2012) Modeling the inhibition of breast cancer growth by GM-CSF. J Theor Biol 303:141-51
Roda, Julie M; Wang, Yijie; Sumner, Laura A et al. (2012) Stabilization of HIF-2? induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol 189:3168-77
Chen, Duan; Roda, Julie M; Marsh, Clay B et al. (2012) Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: a mathematical model. Bull Math Biol 74:2752-77
Roda, Julie M; Sumner, Laura A; Evans, Randall et al. (2011) Hypoxia-inducible factor-2? regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis. J Immunol 187:1970-6